NWBO Northwest Biotherapeutics, Inc. Paradigmenwechsel in Biotech - Phase 3 results (Seite 18)
eröffnet am 25.05.20 16:55:53 von
neuester Beitrag 08.05.24 23:51:31 von
neuester Beitrag 08.05.24 23:51:31 von
Beiträge: 1.199
ID: 1.325.306
ID: 1.325.306
Aufrufe heute: 1
Gesamt: 80.203
Gesamt: 80.203
Aktive User: 0
ISIN: US66737P6007 · WKN: A1J5EY · Symbol: NBYB
0,4300
EUR
0,00 %
0,0000 EUR
Letzter Kurs 31.05.24 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
13.10.23 · PR Newswire (engl.)  |
25.09.23 · Accesswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2554 | +9.943,20 | |
| 7,9600 | +151,90 | |
| 2,3900 | +32,04 | |
| 6,7800 | +30,13 | |
| 3,1100 | +29,05 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,4800 | -17,80 | |
| 9,6000 | -18,64 | |
| 8,6850 | -20,47 | |
| 2,0400 | -58,87 | |
| 0,8020 | -91,06 |
Beitrag zu dieser Diskussion schreiben
Feedback
Was von dieser Firma kommt, bzw nicht kommt,
ist mehr als enttäuschend
ist mehr als enttäuschend
"nette" Erwähnung von DCvax in nature.com
DCs are potent anti-tumoral cells that generate an immune response through presenting tumor antigens to T cells; due to this ability, DC vaccines, such as DCVax-L, are a major focus of attention for immunotherapy of gliomas )21.
Fußnote:
)21. Hdeib, A. & Sloan, A. E. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme. CNS Oncol. 4, 63–69 (2015).
DCs are potent anti-tumoral cells that generate an immune response through presenting tumor antigens to T cells; due to this ability, DC vaccines, such as DCVax-L, are a major focus of attention for immunotherapy of gliomas )21.
Fußnote:
)21. Hdeib, A. & Sloan, A. E. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme. CNS Oncol. 4, 63–69 (2015).
CEO Jade/Kite über ASCO und seinen highlights:
https://www.linkedin.com/feed/update/urn:li:activity:7074065…
dann David Reed, Inhaber Southern IT Group LLC
Good to see the positive comments about NWBIO. "Northwest Biotherapeutics displayed a stunning array of patient testimonials, highlighting gratefulness for being included in trials, to accomplishments in their newfound lease of life, to simply attesting to the value of those extra months and years of life with their family. A truly touching display that drew the reader closer and raised interest in their unique solutions. "
Hopeful for 2023 approval in UK or USA
Read DAN’S STORY,
diagnosed with metastatic thyroid cancer in 2012. He had already been through 5 years of treatment for colon cancer, including multiple rounds of surgery, radiation and chemotherapy.
He began receiving DCVax-L exactly 10 years ago, in May of 2012, for metastatic thyroid cancer, and today he remains in remission.
Read ALICE ´ s STORY,
“My decision to try the investigational DCVax-L immune therapy over traditional cancer therapy was a no brainer. My tumor metastasized twice in 2 years. After 8 months of chemo and radiation for my breast cancer, and 10 years later 1 month of radiation for merkel cell carcinoma, a treatment option to potentially ‘get well without getting sick’ was just what I was looking for.
I’ve been receiving DCVax-L personalized immune therapy since 2012, and find it easy and comfortable.
I feel like I am part of something bigger than me. The people at NW Bio have treated me with dignity and respect. It is an honor to be part of this incredible game changing family and have an opportunity to participate in the development of DCVax-L.
Today I live by this: ‘If it doesn’t make my tail wag, don’t do it!’
DCVax-L has been a tail wagging experience in my book.”
"These are personal experiences of patients who have received the DCVax-L investigational immune therapy, and may not represent the experiences of all patients. DCVax-L has not yet been approved for commercial distribution by the FDA." - NWBio
https://www.linkedin.com/feed/update/urn:li:activity:7074065…
dann David Reed, Inhaber Southern IT Group LLC
Good to see the positive comments about NWBIO. "Northwest Biotherapeutics displayed a stunning array of patient testimonials, highlighting gratefulness for being included in trials, to accomplishments in their newfound lease of life, to simply attesting to the value of those extra months and years of life with their family. A truly touching display that drew the reader closer and raised interest in their unique solutions. "
Hopeful for 2023 approval in UK or USA
Read DAN’S STORY,
diagnosed with metastatic thyroid cancer in 2012. He had already been through 5 years of treatment for colon cancer, including multiple rounds of surgery, radiation and chemotherapy.
He began receiving DCVax-L exactly 10 years ago, in May of 2012, for metastatic thyroid cancer, and today he remains in remission.
Read ALICE ´ s STORY,
“My decision to try the investigational DCVax-L immune therapy over traditional cancer therapy was a no brainer. My tumor metastasized twice in 2 years. After 8 months of chemo and radiation for my breast cancer, and 10 years later 1 month of radiation for merkel cell carcinoma, a treatment option to potentially ‘get well without getting sick’ was just what I was looking for.
I’ve been receiving DCVax-L personalized immune therapy since 2012, and find it easy and comfortable.
I feel like I am part of something bigger than me. The people at NW Bio have treated me with dignity and respect. It is an honor to be part of this incredible game changing family and have an opportunity to participate in the development of DCVax-L.
Today I live by this: ‘If it doesn’t make my tail wag, don’t do it!’
DCVax-L has been a tail wagging experience in my book.”
"These are personal experiences of patients who have received the DCVax-L investigational immune therapy, and may not represent the experiences of all patients. DCVax-L has not yet been approved for commercial distribution by the FDA." - NWBio
und täglich grüßt das Karlchen (fast)
Linda Powers ´ s skills, die gerade in dieser zeit (bought out oder kooperationen) gefragt sind:
Sie war Co-Verhandlungsführerin für die USA beim Nordamerikanischen Freihandelsabkommen, einem Finanzsektorabkommen, das Möglichkeiten für Banken, Wertpapiere, Versicherungen, Pensionsfonds und damit verbundene Bereiche in Kanada und Mexiko eröffnete.
In den 1980er Jahren war Frau Powers als Rechtsanwältin tätig und spezialisierte sich auf Unternehmensfusionen, Übernahmen und Finanzierungen sowie bestimmte Arten von Transaktionen im Bereich des geistigen Eigentums. Während ihrer Tätigkeit am Hauptsitz der Europäischen Union in Brüssel war sie für die Ausarbeitung der ersten Regeln zum Schutz des geistigen Eigentums verantwortlich, die heute die Know-how-Lizenzierung in der Europäischen Union regeln.
She was co-lead negotiator for the U.S. on the North American Free Trade Agreement, financial sector agreement, which opened banking, securities, insurance, pension fund and related opportunities in Canada and Mexico.
During the 1980s, Ms. Powers practiced law, specializing in corporate mergers, acquisitions and financings, and certain kinds of intellectual property transactions. While working for the headquarters of the European Union in Brussels, she was responsible for drafting the initial intellectual property rules that now govern know-how licensing in the European Union.
https://www.c-span.org/video/?c5017935/user-clip-linda-power… .
https://www.ncbi.nlm.nih.gov/books/NBK43800/
https://digitalrepository.unm.edu/usmexlj/vol1/iss1/7
P.S. wer lesen will, der liest - oder einfach ignorieren
Linda Powers ´ s skills, die gerade in dieser zeit (bought out oder kooperationen) gefragt sind:
Sie war Co-Verhandlungsführerin für die USA beim Nordamerikanischen Freihandelsabkommen, einem Finanzsektorabkommen, das Möglichkeiten für Banken, Wertpapiere, Versicherungen, Pensionsfonds und damit verbundene Bereiche in Kanada und Mexiko eröffnete.
In den 1980er Jahren war Frau Powers als Rechtsanwältin tätig und spezialisierte sich auf Unternehmensfusionen, Übernahmen und Finanzierungen sowie bestimmte Arten von Transaktionen im Bereich des geistigen Eigentums. Während ihrer Tätigkeit am Hauptsitz der Europäischen Union in Brüssel war sie für die Ausarbeitung der ersten Regeln zum Schutz des geistigen Eigentums verantwortlich, die heute die Know-how-Lizenzierung in der Europäischen Union regeln.
She was co-lead negotiator for the U.S. on the North American Free Trade Agreement, financial sector agreement, which opened banking, securities, insurance, pension fund and related opportunities in Canada and Mexico.
During the 1980s, Ms. Powers practiced law, specializing in corporate mergers, acquisitions and financings, and certain kinds of intellectual property transactions. While working for the headquarters of the European Union in Brussels, she was responsible for drafting the initial intellectual property rules that now govern know-how licensing in the European Union.
https://www.c-span.org/video/?c5017935/user-clip-linda-power… .
https://www.ncbi.nlm.nih.gov/books/NBK43800/
https://digitalrepository.unm.edu/usmexlj/vol1/iss1/7
P.S. wer lesen will, der liest - oder einfach ignorieren
noch eine zusammenfassung (etwas ausführlicher)
Nov ’02: DCVax-L (“L”) FDA orphan status
Dec ’06: L Phase3 starts
Nov ’07: L EU orphan status
Oct ’10: Poly-ICLC + L combo starts.
Jan ’20: Keytruda + L combo starts
Sep ’20: Flaskworks acquired
Oct ’20: L data lock
Oct ’21: UK Human Tissue License
Aug ‘22: L PIP approved (pediatric)
Nov ’22: L JAMA pub. n+rGBM
Mar ’23: UK Commercial Mfg License & GMP
tweet
https://twitter.com/hoffmann6383/status/1650911955513753619
auch die folgende kommentare sind hochinteressant
Nov ’02: DCVax-L (“L”) FDA orphan status
Dec ’06: L Phase3 starts
Nov ’07: L EU orphan status
Oct ’10: Poly-ICLC + L combo starts.
Jan ’20: Keytruda + L combo starts
Sep ’20: Flaskworks acquired
Oct ’20: L data lock
Oct ’21: UK Human Tissue License
Aug ‘22: L PIP approved (pediatric)
Nov ’22: L JAMA pub. n+rGBM
Mar ’23: UK Commercial Mfg License & GMP
tweet
https://twitter.com/hoffmann6383/status/1650911955513753619
auch die folgende kommentare sind hochinteressant
Trading Spotlight
und nun die dreckige seite des "business"
Erkenntnis
1. naktes shorten gibt es
2. SEC deckt das (sogar) auf und verhängt zus mit doj strafen
3. Sabby LCC hat auch schon nwbo geld gegen warrants und dergleichen verliehen. Hier könnte es mit großer wahrscheinlichkeit auch "schweinereien" gegeben haben. vielleicht hören wir noch davon!
https://www.sec.gov/news/press-release/2023-107
FOR IMMEDIATE RELEASE?2023-107
Washington D.C., June 12, 2023 —
The Securities and Exchange Commission today charged investment adviser Sabby Management LLC and its managing partner, Hal D. Mintz, with fraud in connection with a long running scheme involving misrepresentations and violations of rules for short selling and order making, as well as other violative trading, that generated more than $2 million in illegal profits.
The SEC’s complaint alleges that, from at least March 2017 through May 2019, Sabby and Mintz repeatedly circumvented trading rules to conduct unlawful trades in the stock of at least 10 public companies. Short selling is a legal practice where, generally, a trader borrows a security from a securityholder and sells the security at one price, speculating that the trader can buy the security at a lower price in the future before it must be returned to its owner. As alleged in the complaint, for example, Sabby and Mintz engaged in illegal “naked short selling” by intentionally and improperly placing short sales when they knew or were reckless in not knowing that they had not borrowed or located the shares, and then failed to make timely delivery of the shares. According to the SEC’s complaint, the purpose of Sabby and Mintz’s fraudulent scheme was to earn profits they could not have gained through legal trading.
Additionally, as the complaint alleges, on occasion Sabby and Mintz used their naked short selling to artificially deflate the price of securities, allowing them to obtain more shares at a cheaper price.
The SEC’s complaint further alleges that Sabby and Mintz tried to conceal their fraudulent trading, including by using securities acquired after the trades to make it appear to brokers executing the trades that they had complied with the requirement to have borrowed or located the shares prior to their trades. As the complaint alleges, when questioned by at least one broker regarding their trading, Sabby and Mintz repeatedly lied about the trading.
“The SEC alleges that Sabby and Mintz attempted to game the system and make an illegal profit,” said Carolyn Welshhans, Associate Director of the SEC’s Division of Enforcement. “When someone uses naked shorts or other manipulative practices to cheat the market and investors, the SEC will ensure that they are held accountable.”
The SEC’s complaint, filed in the U.S. District Court for the District of New Jersey, charges Sabby and Mintz with violations of Section 10(b) of the Securities Exchange Act of 1934 and Rules 10b-5 and 10b-21 thereunder. The complaint also charges Sabby with violations of Sections 204 and 206(4) of the Investment Advisers Act of 1940 and Rules 204-2 and 206(4)-7 thereunder and charges Mintz with aiding and abetting those violations. The complaint seeks permanent injunctive relief, disgorgement of ill-gotten gains plus prejudgment interest, and civil penalties.
The SEC’s investigation was conducted by Edward Reilly and Christopher Mathews, with assistance from Patrick McCluskey and Brian Shute, under the supervision of Amy Friedman and Ms. Welshhans. The litigation will be led by Daniel Maher and Mr. Reilly and supervised by David Nasse.
Erkenntnis
1. naktes shorten gibt es
2. SEC deckt das (sogar) auf und verhängt zus mit doj strafen
3. Sabby LCC hat auch schon nwbo geld gegen warrants und dergleichen verliehen. Hier könnte es mit großer wahrscheinlichkeit auch "schweinereien" gegeben haben. vielleicht hören wir noch davon!
https://www.sec.gov/news/press-release/2023-107
FOR IMMEDIATE RELEASE?2023-107
Washington D.C., June 12, 2023 —
The Securities and Exchange Commission today charged investment adviser Sabby Management LLC and its managing partner, Hal D. Mintz, with fraud in connection with a long running scheme involving misrepresentations and violations of rules for short selling and order making, as well as other violative trading, that generated more than $2 million in illegal profits.
The SEC’s complaint alleges that, from at least March 2017 through May 2019, Sabby and Mintz repeatedly circumvented trading rules to conduct unlawful trades in the stock of at least 10 public companies. Short selling is a legal practice where, generally, a trader borrows a security from a securityholder and sells the security at one price, speculating that the trader can buy the security at a lower price in the future before it must be returned to its owner. As alleged in the complaint, for example, Sabby and Mintz engaged in illegal “naked short selling” by intentionally and improperly placing short sales when they knew or were reckless in not knowing that they had not borrowed or located the shares, and then failed to make timely delivery of the shares. According to the SEC’s complaint, the purpose of Sabby and Mintz’s fraudulent scheme was to earn profits they could not have gained through legal trading.
Additionally, as the complaint alleges, on occasion Sabby and Mintz used their naked short selling to artificially deflate the price of securities, allowing them to obtain more shares at a cheaper price.
The SEC’s complaint further alleges that Sabby and Mintz tried to conceal their fraudulent trading, including by using securities acquired after the trades to make it appear to brokers executing the trades that they had complied with the requirement to have borrowed or located the shares prior to their trades. As the complaint alleges, when questioned by at least one broker regarding their trading, Sabby and Mintz repeatedly lied about the trading.
“The SEC alleges that Sabby and Mintz attempted to game the system and make an illegal profit,” said Carolyn Welshhans, Associate Director of the SEC’s Division of Enforcement. “When someone uses naked shorts or other manipulative practices to cheat the market and investors, the SEC will ensure that they are held accountable.”
The SEC’s complaint, filed in the U.S. District Court for the District of New Jersey, charges Sabby and Mintz with violations of Section 10(b) of the Securities Exchange Act of 1934 and Rules 10b-5 and 10b-21 thereunder. The complaint also charges Sabby with violations of Sections 204 and 206(4) of the Investment Advisers Act of 1940 and Rules 204-2 and 206(4)-7 thereunder and charges Mintz with aiding and abetting those violations. The complaint seeks permanent injunctive relief, disgorgement of ill-gotten gains plus prejudgment interest, and civil penalties.
The SEC’s investigation was conducted by Edward Reilly and Christopher Mathews, with assistance from Patrick McCluskey and Brian Shute, under the supervision of Amy Friedman and Ms. Welshhans. The litigation will be led by Daniel Maher and Mr. Reilly and supervised by David Nasse.
hier nochmal "was schönes" von UCLA:
https://www.uclahealth.org/news/fda-approval-brain-cancer-al…
und
vom "UK krebs institut" NIH über den UCLA SPORE TRIAL, der mit 1.dcvax, 2.merck keytruda, 3.poly ICLI und 4. japanische daichy und den besten interimsdaten von 65% überlebenden
https://trp.cancer.gov/spores/abstracts/ucla_brain.htm#h02
https://www.uclahealth.org/news/fda-approval-brain-cancer-al…
und
vom "UK krebs institut" NIH über den UCLA SPORE TRIAL, der mit 1.dcvax, 2.merck keytruda, 3.poly ICLI und 4. japanische daichy und den besten interimsdaten von 65% überlebenden
https://trp.cancer.gov/spores/abstracts/ucla_brain.htm#h02
ist doch interessant wie aus mäßigen Parametern- hier
erst charttechnik - HOLD
dann "läppische" fundamental - BUY
richtige Schlüsse/ Empfehlungen ausgesprochen werden
- klar TST clickbait . . . . . . und anderes
mein HOLD und mein BUY resultiert aber aus
den immensen fundamental Daten / Meilensteinen / eine Vaxxine die die gesamte Medizin auf den Kopf stellen wird
erst charttechnik - HOLD
dann "läppische" fundamental - BUY
richtige Schlüsse/ Empfehlungen ausgesprochen werden
- klar TST clickbait . . . . . . und anderes
mein HOLD und mein BUY resultiert aber aus
den immensen fundamental Daten / Meilensteinen / eine Vaxxine die die gesamte Medizin auf den Kopf stellen wird
Antwort auf Beitrag Nr.: 73.987.914 von janissary am 11.06.23 21:36:11Ich frage mich schon seit langem, was diese computer-generierten Texte bringen sollen. Die gibt es nun ja schon seit Jahren und da werden einfach ein paar Unternehmensdaten und Kennzahlen aus Tabellen übernommen und dann mit ein paar Worthülsen und Beurteilungen sowie Vergleichen in Textform präsentiert, sowie schließlich daraus ein "Rating" zu erstellen.
Im konkreten Fall scheint es aber auch schon an der Datenbasis zu Fehlern gekommen sein (NWBO weist ein KGV von 10,82 auf?).
Dann wird das Ganze noch mit einen spektakulären Überschrift versehen, und ferig ist der Click-Bait.
Im konkreten Fall scheint es aber auch schon an der Datenbasis zu Fehlern gekommen sein (NWBO weist ein KGV von 10,82 auf?).
Dann wird das Ganze noch mit einen spektakulären Überschrift versehen, und ferig ist der Click-Bait.
Durchsuchen
